Abbott Reports Q4 Profit Surge, Projects 2025 Growth

Abbott Laboratories reported a significant increase in fourth-quarter profit, with earnings reaching $9.229 billion or $5.27 per share, compared to $1.594 billion or $0.91 per share the previous year, aligning with analysts' expectations. The company's revenue rose 7.2% to $10.974 billion, driven by strong demand for medical devices, including glucose-monitoring products. For 2025, Abbott forecasts adjusted earnings per share between $5.05 and $5.25, aligning with Wall Street's expectations, and anticipates organic sales growth of 7.5% to 8.5%. The company's stock saw a 2.92% increase, closing at $116.79, reflecting positive market sentiment. Abbott is also projecting improvements in operating margins and growth opportunities from its R&D pipeline, expecting double-digit growth at the midpoint of its earnings forecast. This optimistic outlook is supported by increasing diabetes care awareness and broader insurance coverage for its products.